Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Inclusion Criteria: * Histological diagnosis of lung microcytoma; * Age ≥18 years; * Performance status according to ECOG 0-2; * Extended disease at the time of first line oncological treatment; * Initial staging and restaging after chemo-immunotherapy with CT, CT-PET FDG and brain MRI; * In at least partial response (defined according to the Recist criteria \[18\]) after treatment chemoimmunotherapy according to the Impower 133 scheme; * Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy; * Pulmonary function tests at the time of radiotherapy treatment compatible with irradiation: FEV≥1.2 l or \>40%, DLCO≥50%; * Written informed consent. Exclusion Criteria: * Previous radiotherapy treatment at the thoraco-mediastinal level; * In disease progression after chemo-immunotherapy treatment.